Zacks Small Cap Has Pessimistic Outlook of ARWR Q2 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Zacks Small Cap reduced their Q2 2025 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a report released on Wednesday, February 12th. Zacks Small Cap analyst D. Bautz now anticipates that the biotechnology company will post earnings of ($1.01) per share for the quarter, down from their previous forecast of ($0.97). The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($3.40) per share. Zacks Small Cap also issued estimates for Arrowhead Pharmaceuticals' Q3 2025 earnings at ($1.01) EPS, FY2025 earnings at ($4.39) EPS, FY2026 earnings at ($3.05) EPS and FY2027 earnings at ($2.75) EPS.

A number of other equities research analysts have also weighed in on the company. Royal Bank of Canada restated an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Chardan Capital reiterated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com upgraded Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. Citigroup dropped their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 27th. Finally, Sanford C. Bernstein dropped their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating on the stock in a research report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Stock Up 2.5 %

Shares of ARWR stock traded up $0.49 during trading hours on Friday, reaching $20.44. 1,071,851 shares of the company's stock were exchanged, compared to its average volume of 2,231,834. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $36.72. The stock has a market cap of $2.58 billion, a PE ratio of -4.07 and a beta of 0.95. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The stock's fifty day moving average price is $19.87 and its two-hundred day moving average price is $20.96.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97).

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently modified their holdings of ARWR. Neo Ivy Capital Management purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at about $318,000. Two Sigma Advisers LP grew its stake in Arrowhead Pharmaceuticals by 330.7% during the 4th quarter. Two Sigma Advisers LP now owns 430,700 shares of the biotechnology company's stock worth $8,097,000 after buying an additional 330,700 shares during the last quarter. Two Sigma Investments LP grew its stake in Arrowhead Pharmaceuticals by 281.3% during the 4th quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company's stock worth $14,934,000 after buying an additional 586,062 shares during the last quarter. Tema Etfs LLC purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $1,156,000. Finally, Silvercrest Asset Management Group LLC grew its stake in shares of Arrowhead Pharmaceuticals by 24.7% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 280,511 shares of the biotechnology company's stock valued at $5,274,000 after purchasing an additional 55,622 shares during the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total transaction of $219,456.00. Following the completion of the transaction, the chief executive officer now directly owns 3,764,252 shares in the company, valued at approximately $71,709,000.60. This represents a 0.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider James C. Hamilton sold 32,729 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $648,688.78. Following the transaction, the insider now owns 272,122 shares of the company's stock, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 147,432 shares of company stock valued at $2,957,986. 4.30% of the stock is owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.